IQVIA Holdings Inc. $IQV Shares Sold by Wilkins Investment Counsel Inc.

Wilkins Investment Counsel Inc. decreased its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 5.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 68,363 shares of the medical research company’s stock after selling 3,611 shares during the period. IQVIA makes up approximately 2.2% of Wilkins Investment Counsel Inc.’s investment portfolio, making the stock its 17th largest position. Wilkins Investment Counsel Inc.’s holdings in IQVIA were worth $15,410,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Ameliora Wealth Management Ltd. acquired a new stake in IQVIA in the 4th quarter valued at about $25,000. Physician Wealth Advisors Inc. raised its holdings in IQVIA by 1,340.0% in the 3rd quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 134 shares during the last quarter. Westside Investment Management Inc. raised its holdings in IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company’s stock valued at $30,000 after acquiring an additional 101 shares during the last quarter. Measured Wealth Private Client Group LLC acquired a new stake in IQVIA in the 3rd quarter valued at about $30,000. Finally, Activest Wealth Management raised its holdings in IQVIA by 590.0% in the 4th quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 118 shares during the last quarter. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

NYSE:IQV opened at $157.73 on Friday. The company has a debt-to-equity ratio of 2.09, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $247.04. The stock has a market capitalization of $26.77 billion, a P/E ratio of 20.07, a PEG ratio of 1.57 and a beta of 1.18. The company has a 50 day moving average price of $169.36 and a 200 day moving average price of $201.55.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.40 by $0.02. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The company had revenue of $4.36 billion during the quarter, compared to analysts’ expectations of $4.24 billion. During the same quarter last year, the company posted $3.12 EPS. The firm’s revenue was up 10.3% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 11.5 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on IQV shares. Evercore restated an “outperform” rating and set a $185.00 price target on shares of IQVIA in a report on Wednesday, April 8th. Truist Financial cut their price target on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a report on Thursday, February 19th. UBS Group cut their price target on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a report on Friday, February 6th. JPMorgan Chase & Co. cut their price target on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a report on Friday, February 6th. Finally, Morgan Stanley set a $240.00 price target on shares of IQVIA in a report on Wednesday, February 11th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $226.63.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.